Category Archives: CVNA

Alcoa: Another ‘Chief Cook’

March 18, 2023 By in Biotech, Wyckoff, The Speck, CVNA, ZeroHedge, AA, Spring-to-Up-Thrust, Speck-Effect

Yet, One More ‘ESG’ Opportunity

Like Carvana, Alcoa has no P/E

However, before we get started, this just out concerning Biotech:

From the German Health Minister, no less:

“Permanent Disabilities”

In a way, it does tie into the Alcoa analysis.

As a reminder, the economic (and population) collapse created by protection from ‘The Speck’, will last the lifetime of anyone reading this post (not advice, not a recommendation).

To support that statement and expand on the enormity of what’s happening, we have this link.

‘Over the next 10 years, ‘Speck’ lawsuits are projected to experience tremendous growth.’

With that, let’s move on.

Alcoa & ESG

Just looking at the website, it’s an ESG cornucopia.

When looking at the chart, it’s (almost) a no-brainer.

First, the very long-term view (Quarterly)

Alcoa AA, Quarterly

On the long-term, we have the repeating market characteristic; ‘Spring-to-Up-Thrust.

A ‘test’ of that up-thrust has been occurring over the most recent quarter.

On the weekly chart, we see price action penetrated support with volume increasing.

Alcoa AA, Weekly

Technically, it’s a Wyckoff ‘Spring’ set-up. Some form of upward action next week is to be expected.

However, with the increased volume to the downside, probabilities are low at this point we’ll see any significant upside (not advice, not a recommendation).

Long Way To The ‘Open’

As said in the prior update, events are accelerating. The latest from ZeroHedge proves that to be true.

UBS Seeks Government Backstop As It Rushes To Finalize Credit Suisse Takeover Deal As Soon As Tonight

Another Nail in the Coffin

Looks like the Swedes have put another nail in the coffin for ESG. How long is it going to take for their pension system to fully collapse and then result in social unrest a la Paris?

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Intel … ‘Penny Stock’ by Year End ?

March 4, 2023 By in Barron's, CVNA, INTC, Speck-Effect, The Speck, Wyckoff 3 Comments

Trading Channel

Beginning next week, we’re about to find out if Intel (INTC) is on track to be a ‘penny stock’, by year-end.

Stocks trading below $5/share, are technically called ‘Penny Stocks‘, and mostly ignored by institutional money.

Dystopian Hell: The Stage Is Set

INTC, has already cut the dividend by 66% (note the symbolism) and is ‘conserving cash’.

A large part of their operation with 18,600 employees, is just outside Portland, Oregon.

Here’s a recent look at Portland, uploaded two months ago.

‘Gee honey. Let’s take the kids and move to Portland … Not.’

Incredible, that ‘Speck Protection’ is STILL being pushed (time stamp 2:11). How would you like to work at a location at this late date, where it’s normal to wear a mask?

So, it goes.

All of this brings us to the chart. The price action itself defines the next likely course (Wyckoff).

Intel INTC, Weekly Close

Last week closed testing underside resistance and potential right-side trend line contact (second chart).

Compressing the chart and expanding the downside scale, gives us the following.

Just in case anyone’s skeptical about ‘channels’ not being a real potential, here’s the latest look at Carvana (CVNA).

Carvana CVNA, Weekly Close

It’s important to note, not only the channel but the location of “No P/E”, which was the release of this post.

Carvana never closed higher after December 11th, 2021.

Intel, What’s Next?

Will it be the same for Intel?

Of course, that’s not known. Price action itself is the final arbiter; at this juncture, it’s at The Danger Point®

This is where the risk is least (not advice, not a recommendation).

If price action moves significantly higher from here, let’s say 5%, then we’ve likely bottomed and are heading into a rebound.

If not, and Monday, opens and closes lower, it may be a confirmation of the right-side trend line and potential trading channel (not advice, not a recommendation).

Let’s see what happens next.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

CarMax … Dead Cat Bounce

February 4, 2023 By in CVNA, David Weis, KMX, Spring-to-Up-Thrust, VIX-Calendar, Wyckoff

That, Was Then …

Back in October last year, the update on CarMax, said this:

“… there could be small blip up to resistance in the 85-area before potentially rolling over into a descent that projects to the 4.00, level.

If and when that happens, CarMax rival Carvana, may be long gone; its disruptive vending machines possibly being used as homeless shelters or insect farms.”

Even with the short-squeeze mania last week, rival Carvana, remains down a blistering – 96.2%, from its all-time highs; having reached an interim low of – 99.1%, in December.

Insect farms, dead-ahead. 🙂

The ‘Bounce’

So, does getting to a high of KMX 80.92, meet the forecast of “the 85-area” ?

It looks close enough, but the real story is the bearish trade set-up.

I’ve lost track of the number of Wyckoff ‘Spring to Up-Thrust’, set-ups that have been covered since this post, over sixteen months ago; we now have another.

CarMax KMX, Weekly

Unmarked chart.

Long time users should be able to spot the set-up immediately.

For those new to the site or if more clarification is needed, here it is:

Getting down to the daily, is where a trading plan is created.

KMX, Daily

Several scenarios.

Three potential scenarios are below.

Remember, we’re in possibly the largest bull-trap in market history.

Those in control of the markets need to bleed-off the VIX Call options values by having the market go up, sideways, or down slowly (at first).

Here is the VIX Option expiration calendar for 2023-2025.

Going straight down at this juncture (although anything can happen), is not the most probable outcome.

Scenario No. 1

Lower open at the next session, followed by a labored move to test the underside of resistance.

The test can happen in one day or several days.

Scenario No. 2

Next up, is congestion tests before heading lower.

Scenario No. 3

Lastly, a steady but ratcheting move lower.

These are just three potential outcomes of an infinite number.

The market itself will give clues at the next session to the more probable outcome.

Summary

It may be after the 15th (past VIX option expiration), before there is a decisive move lower.

Not covered in this update is what happens if KMX, actually goes higher instead of lower. If that happens, we’ll post updates as necessary.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Claus & Effect, The Next Wave

December 24, 2022 By in $SPSIBI, Biotech, Catherine Austin Fitts, CVNA, NFLX, SPBIO, Speck-Effect, TGT, The Speck, Useful Idiots, ZeroHedge 1 Comment

Unprecedented … Again

Nefarious forces operate in distraction and darkness.

“And this is the condemnation, that light is come into the world, and men loved darkness rather than light, because their deeds were evil.”

The year 2021, was the year everyone (except children) showed their true colors; they made their decision, knowingly or not, for darkness or light.

This year, 2022, is where the effects (or ‘side effects’) of that decision began to take hold.

Now, as 2023 approaches, we’re likely to move into the realm of unprecedented chaos and collapse.

As if on cue, under the cloak of this week’s holiday distraction, we have what’s possibly the next wave.

This could be the reason as presented in the last update, why biotech appears to be in the early stages of disconnecting from the overall market.

That separation may continue or not; price action is always the final arbiter.

The ‘Woke’ Go Broke

The useful idiots that comprise the ‘woke’ business crowd may be in for the biggest surprise in the coming year.

If there is one overriding theme to keep in mind for 2023, this could be it.

Separate enclaves are now forming of those who have not, will not, and are not going to go along with the ever more unbelievable narratives.

Here is a link to just one of those enclaves.

As a digression; in Texas, we’re just now coming out of yet another record-breaking cold spell.

That’s two, never before seen record breaking low temp events within the past three years!

How does that fit with the global warming narrative?

Anyone awake knows full well what’s going on … and it’s not global warming.

Who’s On First: NFLX or TGT?

Now that vending machine Carvana (CVNA), is out of the way, who’s next?

Partly as a result of economic decline and partly from the decision to take consumer spending elsewhere, Netflix and Target now appear ready to continue their implosion.

More on their technical chart conditions in the next update.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Fake Data, Fake Market, Real Price

December 17, 2022 By in CVNA, Great Depression, Neil McCoy-Ward, NFLX, Wyckoff, ZeroHedge

‘Head Fake’ … 1-million Jobs

Within the mirage of fake data, one thing’s not fake, the price.

The latest revelation about fake data, comes at this link, telling us something we already knew; the jobs data is a complete mirage.

What must be over a year ago, Neil McCoy–Ward, presented a series whereby he reviewed several individual, personal diaries, from The Great Depression.

From that series, no-one (in the public) seemed to know the extent of unemployment until much later.

The numbers were ‘hidden’ back then, just like now; what a coincidence.

The search, and need for the ‘truth’, becomes more clear by the day. In the markets, truth is the price and price only.

Apparently driving it home, revelation that chief cook and (woke) bottle washer Netflix, drank the Kool-Aid and overestimated advertising demand.

The last update on NFLX, stated there may be a rally to test the breakdown. So far, it hasn’t happened.

Last Thursday’s – 8.6%, ‘air-pocket’, may have been the kick-off to much lower prices (not advice, not a recommendation).

Let’s take another look at the big picture on Netflix.

Netflix NFLX, Weekly

Very quickly we see the overall (impulsive) direction of the market is down.

In Wyckoff terms, there’s what he called ‘ease-of-movement’, to the downside.

Next, we have a possible Head & Shoulders, top.

If NFLX, reverses from here all the way down to the neckline (blue line), and if it breaks that line, then we target the 40-area; that’s a lot of ‘ifs’.

Moving in closer on the daily chart, is the following:

Netflix NFLX, Daily

The wedge breakdown is clear.

There was an attempt to rally, if you can call it that, on Friday. So far, no significant upside action.

The zoom area shows price action still below the lower wedge boundry.

Netflix is different from our other potential implosion, short candidate (which proved correct), Carvana, CVNA.

That difference, Carvana sold a product for which there was an actual need, i.e., transportation.

Summary

It’s been just over a year since the CVNA, ‘No P/E’, report.

Carvana’s a slow-motion train-wreck; down over -98%, as of Friday’s close.

Netflix?

Let’s see what happens next.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … Breakdown, Imminent

December 9, 2022 By in $SPSIBI, Biotech, CVNA, Elliott Wave, LABD, LABD-22-14, Positions, Prechter, SPBIO

Waiting For A New Daily Low

Price action leads the news.

As with the Carvana analysis, a year ago which said CVNA, would likely not survive, so too it would appear, biotech is about to join the ranks.

Join the ranks but for different reasons.

Price action leading the news was a concept presented decades ago by Robert Prechter Jr., as part of his Elliott Wave Theory.

His view was the market indicates ‘social mood’; in that case, the market must go down first, before the bad news comes out.

In effect, the public has to be ready and actually want bad news and/or be ready for unexpected, cataclysmic events.

It’s the complete opposite of the accepted mantra, from financial advisors and media alike.

The bear flag in biotech SPBIO, has been forming now for three months. In the history of this sector, there’s never been anything like it.

The last update said there’s been a change in the character of price action; that SPBIO, is heading lower and about to threaten the bottom of the flag.

As we’ll see from the daily chart, indeed we’re getting close.

At this point, there’s no apparent demand for the upside.

Biotech SPBIO, Daily

The change in character is clear. We’re pulling away from the top of the flag and now, hovering at the lows.

Switching gears and going to the 3X leveraged inverse fund LABD, on the daily basis, we see repeating trend lines.

SPBIO, 3X Leveraged Inverse LABD, Daily

As the magenta arrow shows, we’re looking for a new daily high in LABD, to confirm the trendline; that high would naturally correspond to a new daily low in SPBIO.

As of this post (1:02 p.m., EST) neither one has occurred.

Summary

Even as the overall markets are mixed to slightly higher, SPBIO, is posting down – 1.51%; a possible indication it may lead to the downside.

Just exactly what ‘news’ is about to come out is unknown.

However, at this juncture with action pressing lower, it appears, the market is ready.

Positioning

Not advice, not a recommendation.

LABD-22-14

Entry@ 18.905, 18.95*** Stop @ 18.36***

Note: Positions may be increased, decreased, entered, or exited at any time.

***, Indicates change

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The Market Set-Up … This Week

November 13, 2022 By in Biotech, Crypto, CVNA, GDXJ, GLD, Gold Miners, Goldman, HOOD, J.P. Morgan, JDST, JDST-22-05, LABD, LABD-22-10, Michael Cowan, Positions, SPBIO, TSLA, Wyckoff, Wyckoff Stock Market Institute, ZeroHedge 1 Comment

What To Watch … Crypto Collapse, Biotech, Gold, Telsa

JPMorgan … says sell

Goldman … says buy.

Wyckoff says … Don’t listen to either.

In fact, Wyckoff’s stock market training course, first published in 1934, (still available), says that until you can ignore the financial press completely, ‘You will never be successful in the markets’.

Price action itself, properly interpreted, will tell you where to look for the opportunity.

The Ponzi Implosion, Cometh

The market is littered with Ponzi schemes. Some have already imploded, CVNA, HOOD, Crypto; some have not.

Concerning Crypto, here’s an excellent update from Michael Cowan. Buried in that update, at time stamp 4:58, looks like HOOD, may be in even more trouble.

Biotech is in a class of its own and was discussed in yesterday’s update.

For gold, we’re going to look at the Junior Miners GDXJ, and last week’s action.

Junior Miners GDXJ, Daily Close

The Junior’s are the weakest in the sector; therefore, that’s where we look for a short opportunity (not advice, not a recommendation).

To move higher, above resistance, normal market behavior, is to come back to the lower blue line (i.e., support) to gain enough energy to move higher for a breakout.

To move lower, normal market behavior, is to come down to the lower blue line as a test which subsequently fails; the move continues lower.

Either way, normal behavior at this juncture, is to move lower. We’ll see.

Now on to the chief cook and bottle washer … Tesla.

Tesla (TSLA), At The Edge

For starters, let’s recognize there’re a lot of moving parts; U.S. ‘parts’ and China ‘parts’.

If one’s going short, another task is to forecast under what conditions a short would have enough risk removed.

For that answer, oddly enough, we go to gold, GLD.

Gold GLD, Weekly: 2015 – 2017

GLD posted a massive upthrust above the blue line lasting over fourteen weeks before breaking decisively lower.

Then, it labored four weeks to come back up for a test.

After that, collapse; lower weekly closes for seven consecutive weeks.

In the chart above, the area identified as ‘Short’, has as much upside risk removed as possible, right at resistance.

Now on to Tesla.

Tesla TLSA, Weekly

Two scenarios are presented where risk may be reduced.

Chart 1

Chart 2

One of these may happen or neither of them.

Either way, for risk to be reduced, a short entry is needed to be at a known resistance level (not advice, not a recommendation).

Let’s move on to the current positioning.

Positions: (courtesy only, not advice).

One of three events will happen at the next session.

1: Both positions stopped out

2: One position stopped out

3: No positions stopped out

Each outcome will provide a data-point where to focus (or not) in the current environment.

LABD-22-10:

Entry @ 18.1398: Stop @ 16.83

JDST-22-05

Entry @ 9.1666: Stop @ 8.79

Note: Positions may be increased, decreased, entered, or exited at any time.

***, Indicates change

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

CarMax Crash … What’s Next ?

October 2, 2022 By in Activist Post, CVNA, KMX, Mass Psychosis, Michael Cowan 1 Comment

First, The Dead Cat Bounce …

What was said back then …

“As the economy (if you can call it that) falls off the cliff, one of these two (KMX, CVNA), is not likely to survive.”

It looks like Carvana is swirling down its ‘disruptive’ vending machine wormhole, leaving CarMax to pick up whatever’s left of the car ‘consumer’.

The latest earnings release of KMX, confirms what’s left of the typical consumer’s purchasing power, is evaporating if not completely gone.

Still Clueless …

It’s not necessarily the linked earnings report on KMX that’s important, but the comments.

We’ll not call out any specific one but after reading them, there’s an uneasy sense, the typical American is still wandering around in a type of hypnotic, delusional state, namely, mass psychosis.

They’re stunned … ‘looking for the bottom’.

Everyone has their own timeframe but let’s see where an ultimate bottom for KMX, might be on the charts below.

CarMax, KMX, Yearly Chart

The big … big picture

There are three-months left in the year but already the thrust energy lower (magenta arrow) for KMX, is the highest in nearly 26-years of data presented.

Not even the ’08 – ’09, meltdown had downside energy anywhere close to what’s happening now.

That’s a clue in itself, we’ve got a long way to go.

How long, is long?

The quarterly chart of KMX gives us a clue where we might see a ‘bottom’.

CarMax, KMX, Quarterly Chart

Above, we’ve got a terminating wedge (blue lines) that’s been decades in the making.

As the magenta arrow shows, there could be small blip up to resistance in the 85-area before potentially rolling over into a descent that projects to the 4.00, level.

If and when that happens, CarMax rival Carvana, may be long gone; its disruptive vending machines possibly being used as homeless shelters or insect farms.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

No P/E ? … No Problem … Yet

August 14, 2022 By in Biotech, CVNA, LABD, LABD-22-05, Livermore, Loeb, Positions, SPBIO, TDA-LABD-22-02, Wyckoff 1 Comment

Biotech SPBIO, Has No P/E

Is this like Carvana on steroids?

Looking at the top ten components of the SPBIO sector, making up over 14%, of the weighting, none have a P/E ratio.

The three largest weightings are listed below along with hyperlinks to their corporate summaries or research.

Beam Therapeutics Inc.: BEAM

Twist Biosciences Corp.: TWST

Fate Therapeutics Inc.: FATE

The Return on Equity for the list is Negative – 31.9%

With returns like that, it’s unlikely a positive P/E, is showing up anytime soon.

The Market Itself

Livermore worked to prefect his technique, searching for what’s going to happen in a ‘big way’.

Wyckoff discovered the market itself, decides on its next likely course.

Loeb presented the power of ‘focus’; Concentrated positions that eschewed the mediocre mantra of ‘a well-diversified portfolio’.

It’s important to note, Loeb was the former Vice Chairman of E.F. Hutton. The old commercials from the 70s, like the one linked here, were talking about him: ‘When Loeb talks, people listen’.

The Biotech Short

The vultures are circling this sector.

We’ve already shown in the last update, speculative volume on the 3X Inverse fund LABD, is literally off the chart.

The corporate links above, give us a potential ‘why’ for their short positioning.

All three of those companies have a common theme.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The Moderna Reversal

August 9, 2022 By in CVNA, MRNA, Random Notes, Wyckoff 2 Comments

‘Whistling Past The Graveyard’

Moderna (MRNA) appears likely to join the ranks of Carvana (CVNA), with a decline from all-time highs that’s well over -90%.

Even a ‘modest’ projection (as we’ll see below) puts the downside potential for MRNA, far below current levels.

Starting with the weekly chart, MRNA, has just barely retraced upward to an anemic 23.6%, before breaking to the downside.

Moderna MRNA, Weekly Chart

Zoom version below

The Wyckoff up-thrust (reversal), will be confirmed if/when MRNA pushes below last week’s low of 160.06

Projected Decline Over -90%

Unless it’s negated, the weak retrace (23.6%), tells us that MRNA, is probably just getting started to the downside.

Using a modest 1 : 1, projection from current levels, we have MRNA’s downside potential to the 45-area; representing a decline from all-time highs, of approximately -90.9%.

However, for such a weak equity (at this point), the decline also has the possibility to go a bit further, to a 1 : 1.382 projection (shown as the lower arrow).

Declining to the 27-area, would put MRNA, down a stiff -94.6%, from all-time highs.

If MRNA gets to those levels, that’s when the fun starts.

Class Action?

Recall, we’re using the Carvana Crash as the model, right?

Let’s hold that thought and go way back to October 17th, of last year. Reviewing the first bullet item of this post; some of which is repeated below, it said:

“Whenever a high-flyer darling stock changes course and reverses down in a big way, the lawsuits start.

‘Investors’ only know one direction … up.

They figure they’re so smart, any decision from them that does not work out, must be someone else’s fault.

Class Action for Moderna (with discovery) may be dead ahead.

Let’s start our stopwatch and see how long it takes for the first ‘Notice’.”

Getting back to Carvana (CVNA), it posted recent lows on July 14th this year. That was a decline (from all-time highs) of -95%.

Three weeks after that low, and just days ago on August 4th, we get ‘Notice of Class Action‘.

Tick, Tock …

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279